MoleMap combines its proven skin-mapping system with skin cancer expertise to track changes over time as an effective way to detect melanoma early when it’s most treatable. Turnover: $11.8 million Staff numbers: 95 Compound annual growth rate: 18% Export percentage: It has 37 clinics in Australia and the US.
Adrian Bowling – co-founder and chief technology officer of melanoma surveillance company MoleMap – says it has enhanced rather than threatened the dermatology sector.
“We didn’t steal from the dermatologists, we actually grew the market,” the 69-year-old says.
Bowling says the
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).